Sponsor:
UCLA
Code:
NCT05975580
Conditions
Obesity
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
Topiramate
Phentermine
Placebo
Brief summary:
Conditions
Obesity
Study ID
NCT05975580
Start date
Aug 29, 2023
Status verified date
Jun, 2026
Completion date
Jan 31, 2028
Anticipated
Primary completion date
Jul 31, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Enrollment
120 participants
Anticipated
Allocation
Randomized
Intervention Model
Sequential
Primary purpose
Treatment
Arms
experimental: Group A: Topiramate 50 mg
experimental: Group B: Topiramate 100 mg
experimental: Group C: Phentermine 15 mg/Topiramate 100 mg
experimental: Group D: Phentermine 15 mg
experimental: Group E: Phentermine 30 mg
experimental: Group F: Phentermine 15 mg/Topiramate 100 mg
placebo comparator: Group P: Placebo
Interventions
Topiramate
Phentermine
Placebo
Primary outcome measure
Central contacts
Qin Wang
qinw15@hs.uci.eduLocations
University of California Irvine Medical Center
Recruiting
Orange, California, United States, 92868
Contacts
Qin Wang
qinw15@hs.uci.eduPrincipal Investigator:
Kishore M Gadde, MD
Sponsor
University of California, Irvine
Last update posted
Jun 9, 2026
Last verified
Jun, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, Irvine on 2026-06-09.